- 理想的成長型公司, 本業EPS的成長幅度會大於營收的成長幅度
- 營收到某個數字後, 本業EPS呈現不成比例的增加, 有可能是規模經濟的效應
- 如果是有淡旺季的公司, 是否有淡季不淡, 旺季更旺的情況
- 漲很多的股票要留意 EPS 較上季是否有大幅衰退的情況
- 如果EPS衰退，要觀察同業是不是有一樣的狀況
- 要留意增資減資和公司債對股本及EPS的影響
| 加權平均股數 QoQ YoY | EPS QoQ YoY | 本業EPS QoQ YoY | 累計EPS QoQ YoY | 營收 QoQ YoY | 毛利率(%) QoQ YoY | 營業利益率 QoQ YoY | 稅後淨利率 QoQ YoY | 營業利益 QoQ YoY | 稅後淨利 QoQ YoY | 稅前淨利率(%) QoQ YoY | 稅後淨利率(%) QoQ YoY | 兩季平均(YOY)營收成長率(%) | 兩季平均(YOY)EPS成長率(%) | 兩季平均(YOY)本業EPS成長率(%) | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 24Q3 (20) | 131 | 8.26 | 14.91 | -0.05 | 72.22 | 79.17 | -0.02 | 86.67 | 91.3 | -0.64 | -8.47 | 27.27 | 1.9 | 54.47 | 179.41 | 50.38 | -18.53 | -26.95 | 4.79 | 132.92 | 108.4 | 2.95 | 117.46 | 105.54 | 0.09 | 150.0 | 123.08 | -0.07 | 68.18 | 74.07 | 2.95 | 117.53 | 105.55 | 2.95 | 117.46 | 105.54 | 61.48 | 64.16 | 71.28 |
| 24Q2 (19) | 121 | 3.42 | 6.14 | -0.18 | 56.1 | 18.18 | -0.15 | 55.88 | 21.05 | -0.59 | -43.9 | 7.81 | 1.23 | 68.49 | 78.26 | 61.84 | 3.97 | 0.78 | -14.55 | 79.84 | 62.57 | -16.90 | 77.73 | 56.05 | -0.18 | 66.04 | 33.33 | -0.22 | 54.17 | 12.0 | -16.83 | 77.8 | 56.1 | -16.90 | 77.73 | 56.05 | 21.88 | 25.48 | 19.32 |
| 24Q1 (18) | 117 | 2.63 | 2.63 | -0.41 | -5.13 | 4.65 | -0.34 | -17.24 | 0.0 | -0.41 | 67.72 | 4.65 | 0.73 | -24.74 | 97.3 | 59.48 | -9.08 | 24.85 | -72.19 | -43.49 | 44.44 | -75.89 | -35.13 | 46.71 | -0.53 | -8.16 | -10.42 | -0.48 | -9.09 | 2.04 | -75.80 | -35.24 | 46.77 | -75.89 | -35.13 | 46.71 | 8.96 | -33.81 | -21.66 |
| 23Q4 (17) | 114 | 0.0 | 0.0 | -0.39 | -62.5 | 2.5 | -0.29 | -26.09 | -3.57 | -1.27 | -44.32 | 9.93 | 0.97 | 42.65 | 44.78 | 65.42 | -5.15 | 108.15 | -50.31 | 11.81 | 11.55 | -56.16 | -5.41 | 20.44 | -0.49 | -25.64 | -28.95 | -0.44 | -62.96 | 4.35 | -56.05 | -5.4 | 20.6 | -56.16 | -5.41 | 20.44 | 20.60 | -35.80 | -23.57 |
| 23Q3 (16) | 114 | 0.0 | 0.0 | -0.24 | -9.09 | -4.35 | -0.23 | -21.05 | 0.0 | -0.88 | -37.5 | 12.87 | 0.68 | -1.45 | 61.9 | 68.97 | 12.4 | 16.94 | -57.05 | -46.77 | 22.56 | -53.28 | -38.57 | 17.04 | -0.39 | -44.44 | -25.81 | -0.27 | -8.0 | -3.85 | -53.18 | -38.71 | 17.18 | -53.28 | -38.57 | 17.04 | 42.52 | 19.88 | 11.53 |
| 23Q2 (15) | 114 | 0.0 | -30.06 | -0.22 | 48.84 | 4.35 | -0.19 | 44.12 | 32.14 | -0.64 | -48.84 | -16.36 | 0.69 | 86.49 | 97.14 | 61.36 | 28.8 | 12.5 | -38.87 | 70.09 | 64.45 | -38.45 | 73.0 | 65.31 | -0.27 | 43.75 | 28.95 | -0.25 | 48.98 | 32.43 | -38.34 | 73.08 | 65.3 | -38.45 | 73.0 | 65.31 | 20.85 | 20.67 | 11.34 |
| 23Q1 (14) | 114 | 0.0 | -30.06 | -0.43 | -7.5 | -34.37 | -0.34 | -21.43 | 12.82 | -0.43 | 69.5 | -34.37 | 0.37 | -44.78 | 5.71 | 47.64 | 51.57 | 45.87 | -129.94 | -128.45 | 15.72 | -142.41 | -101.74 | 10.0 | -0.48 | -26.32 | 11.11 | -0.49 | -6.52 | 5.77 | -142.41 | -101.74 | 10.0 | -142.41 | -101.74 | 10.0 | 7.37 | -40.70 | -21.59 |
| 22Q4 (13) | 114 | 0.0 | -25.0 | -0.40 | -73.91 | -37.93 | -0.28 | -21.74 | 9.68 | -1.41 | -39.6 | -42.42 | 0.67 | 59.52 | 81.08 | 31.43 | -46.71 | -39.31 | -56.88 | 22.79 | 50.35 | -70.59 | -9.92 | 42.84 | -0.38 | -22.58 | 11.63 | -0.46 | -76.92 | -4.55 | -70.59 | -9.94 | 42.84 | -70.59 | -9.92 | 42.84 | 39.76 | -36.95 | -1.94 |
| 22Q3 (12) | 114 | -30.06 | -30.06 | -0.23 | 0.0 | 25.81 | -0.23 | 17.86 | 36.11 | -1.01 | -83.64 | -40.28 | 0.42 | 20.0 | 0.0 | 58.98 | 8.14 | 73.01 | -73.67 | 32.62 | 41.87 | -64.22 | 42.06 | 52.45 | -0.31 | 18.42 | 41.51 | -0.26 | 29.73 | 48.0 | -64.21 | 41.89 | 52.46 | -64.22 | 42.06 | 52.45 | 10.00 | 14.06 | 23.04 |
| 22Q2 (11) | 163 | 0.0 | 15.6 | -0.23 | 28.12 | 46.51 | -0.28 | 28.21 | 34.88 | -0.55 | -71.88 | -37.5 | 0.35 | 0.0 | -25.53 | 54.54 | 66.99 | 525.46 | -109.34 | 29.08 | 18.52 | -110.83 | 29.96 | 23.83 | -0.38 | 29.63 | 38.71 | -0.37 | 28.85 | 39.34 | -110.50 | 30.17 | 24.0 | -110.83 | 29.96 | 23.83 | -2.71 | 8.89 | 1.20 |
| 22Q1 (10) | 163 | 7.24 | 17.27 | -0.32 | -10.34 | -900.0 | -0.39 | -25.81 | -5.41 | -0.32 | 67.68 | -900.0 | 0.35 | -5.41 | -51.39 | 32.66 | -36.94 | 82.25 | -154.17 | -34.56 | -105.75 | -158.24 | -28.14 | -45111.43 | -0.54 | -25.58 | 0.0 | -0.52 | -18.18 | -1140.0 | -158.24 | -28.14 | -21198.67 | -158.24 | -28.14 | -45111.43 | -8.66 | -1.94 | -5.96 |
| 21Q4 (9) | 152 | -6.75 | 14.29 | -0.29 | 6.45 | -93.33 | -0.31 | 13.89 | -210.0 | -0.99 | -37.5 | 23.85 | 0.37 | -11.9 | -57.47 | 51.79 | 51.92 | 25.83 | -114.57 | 9.6 | -709.11 | -123.49 | 8.57 | -402.6 | -0.43 | 18.87 | -258.33 | -0.44 | 12.0 | -109.52 | -123.49 | 8.57 | -435.75 | -123.49 | 8.57 | -402.6 | -11.27 | 17.18 | 15.09 |
| 21Q3 (8) | 163 | 15.6 | 17.27 | -0.31 | 27.91 | 18.42 | -0.36 | 16.28 | 0.0 | -0.72 | -80.0 | 38.46 | 0.42 | -10.64 | 20.0 | 34.09 | 290.94 | 14.09 | -126.73 | 5.56 | 8.85 | -135.06 | 7.18 | 14.25 | -0.53 | 14.52 | -8.16 | -0.5 | 18.03 | 5.66 | -135.06 | 7.11 | 14.25 | -135.06 | 7.18 | 14.25 | -22.68 | -573.54 | 0.03 |
| 21Q2 (7) | 141 | 1.44 | 9.3 | -0.43 | -1175.0 | -2.38 | -0.43 | -16.22 | -19.44 | -0.40 | -1100.0 | 49.37 | 0.47 | -34.72 | -30.88 | 8.72 | -51.34 | -69.34 | -134.19 | -79.09 | -73.33 | -145.51 | -41474.29 | -63.48 | -0.62 | -14.81 | -19.23 | -0.61 | -1320.0 | -12.96 | -145.39 | -19485.33 | -65.27 | -145.51 | -41474.29 | -63.48 | -25.98 | -524.16 | -143.11 |
| 21Q1 (6) | 139 | 4.51 | 10.32 | 0.04 | 126.67 | 111.11 | -0.37 | -270.0 | -12.12 | 0.04 | 103.08 | 111.11 | 0.72 | -17.24 | -7.69 | 17.92 | -56.46 | -24.26 | -74.93 | -429.17 | -28.9 | -0.35 | 98.58 | 99.43 | -0.54 | -350.0 | -20.0 | 0.05 | 123.81 | 110.87 | 0.75 | 103.25 | 101.22 | -0.35 | 98.58 | 99.43 | 65.66 | 93.60 | -98.89 |
| 20Q4 (5) | 133 | -4.32 | 20.91 | -0.15 | 60.53 | 81.93 | -0.10 | 72.22 | 73.68 | -1.30 | -11.11 | 47.58 | 0.87 | 148.57 | -1.14 | 41.16 | 37.75 | 687.0 | -14.16 | 89.82 | 76.78 | -24.57 | 84.4 | 77.24 | -0.12 | 75.51 | 77.78 | -0.21 | 60.38 | 76.92 | -23.05 | 85.37 | 78.6 | -24.57 | 84.4 | 77.24 | - | - | 0.00 |
| 20Q3 (4) | 139 | 7.75 | 0.0 | -0.38 | 9.52 | 0.0 | -0.36 | 0.0 | 0.0 | -1.17 | -48.1 | 0.0 | 0.35 | -48.53 | 0.0 | 29.88 | 5.06 | 0.0 | -139.03 | -79.58 | 0.0 | -157.51 | -76.96 | 0.0 | -0.49 | 5.77 | 0.0 | -0.53 | 1.85 | 0.0 | -157.51 | -79.05 | 0.0 | -157.51 | -76.96 | 0.0 | - | - | 0.00 |
| 20Q2 (3) | 129 | 2.38 | 0.0 | -0.42 | -16.67 | 0.0 | -0.36 | -9.09 | 0.0 | -0.79 | -119.44 | 0.0 | 0.68 | -12.82 | 0.0 | 28.44 | 20.2 | 0.0 | -77.42 | -33.18 | 0.0 | -89.01 | -44.83 | 0.0 | -0.52 | -15.56 | 0.0 | -0.54 | -17.39 | 0.0 | -87.97 | -43.13 | 0.0 | -89.01 | -44.83 | 0.0 | - | - | 0.00 |
| 20Q1 (2) | 126 | 14.55 | 0.0 | -0.36 | 56.63 | 0.0 | -0.33 | 13.16 | 0.0 | -0.36 | 85.48 | 0.0 | 0.78 | -11.36 | 0.0 | 23.66 | 352.39 | 0.0 | -58.13 | 4.69 | 0.0 | -61.46 | 43.07 | 0.0 | -0.45 | 16.67 | 0.0 | -0.46 | 49.45 | 0.0 | -61.46 | 42.95 | 0.0 | -61.46 | 43.07 | 0.0 | - | - | 0.00 |
| 19Q4 (1) | 110 | 0.0 | 0.0 | -0.83 | 0.0 | 0.0 | -0.38 | 0.0 | 0.0 | -2.48 | 0.0 | 0.0 | 0.88 | 0.0 | 0.0 | 5.23 | 0.0 | 0.0 | -60.99 | 0.0 | 0.0 | -107.95 | 0.0 | 0.0 | -0.54 | 0.0 | 0.0 | -0.91 | 0.0 | 0.0 | -107.73 | 0.0 | 0.0 | -107.95 | 0.0 | 0.0 | - | - | 0.00 |
| 年/月 | 營收 | 月增率(%) | 去年同期年增率(%) | 累計營收 | 累計營收年增率(%) | 近三月累計營收 | 存貨銷售比 | 自結稅前EPS | 自結稅前累計EPS | 備註(年增率變動50%需說明原因) |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024/10 | 0.48 | -28.92 | 111.09 | 4.34 | 120.33 | 1.67 | N/A | 因新藥/學名藥產品出貨較去年同期增加，故營收成長。 | ||
| 2024/9 | 0.67 | 28.83 | 48.59 | 3.87 | 121.53 | 1.9 | 1.08 | 因新藥/學名藥產品出貨較去年同期增加，故營收成長。 | ||
| 2024/8 | 0.52 | -27.13 | 306.19 | 3.2 | 146.94 | 1.85 | 1.11 | 因新藥/學名藥產品出貨較去年同期多，致本期營收成長 | ||
| 2024/7 | 0.71 | 16.32 | 597.99 | 2.68 | 129.45 | 1.7 | 1.21 | 因新藥/學名藥產品出貨較去年同期多，致本期營收成長 | ||
| 2024/6 | 0.61 | 66.48 | 71.63 | 1.96 | 84.42 | 1.23 | 1.2 | 因新藥/學名藥產品出貨較去年同期多，致本期營收成長 | ||
| 2024/5 | 0.37 | 49.69 | 172.51 | 1.35 | 90.9 | 1.1 | 1.34 | 因新藥/學名藥產品出貨較去年同期多，致本期營收成長 | ||
| 2024/4 | 0.25 | -49.3 | 22.06 | 0.98 | 71.57 | 0.87 | 1.69 | 因新藥/學名藥產品出貨較去年同期多，致本期營收成長 | ||
| 2024/3 | 0.49 | 240.5 | 256.43 | 0.73 | 98.6 | 0.73 | 0.83 | 藥品銷售收入增加 | ||
| 2024/2 | 0.14 | 35.08 | 36.14 | 0.25 | 6.41 | 0.92 | 0.66 | - | ||
| 2024/1 | 0.11 | -84.38 | -17.82 | 0.11 | -17.82 | 0.85 | 0.72 | - | ||
| 2023/12 | 0.68 | 892.89 | 286.4 | 2.72 | 51.83 | 0.97 | 0.43 | 藥品銷售及委託開發收入增加 | ||
| 2023/11 | 0.07 | -69.8 | -76.53 | 2.04 | 26.38 | 0.74 | 0.56 | 新藥銷售及委託開發收入減少 | ||
| 2023/10 | 0.23 | -49.97 | 11.16 | 1.97 | 48.96 | 0.8 | 0.52 | - | ||
| 2023/9 | 0.45 | 252.18 | 150.43 | 1.75 | 55.81 | 0.68 | 0.65 | 學名藥銷售增加且委託開發收入本期完工比例較高，故本期營收增加 | ||
| 2023/8 | 0.13 | 25.21 | 136.37 | 1.29 | 37.69 | 0.59 | 0.75 | 新藥/學名藥收入本月增加，故營收增加 | ||
| 2023/7 | 0.1 | -71.39 | -45.07 | 1.17 | 31.65 | 0.6 | 0.74 | - | ||
| 2023/6 | 0.36 | 164.33 | 75.64 | 1.06 | 52.07 | 0.69 | 0.43 | 委託開發收入因本期完工比例較高且學名藥銷售增加，故本期營收增加 | ||
| 2023/5 | 0.14 | -32.94 | 44.92 | 0.71 | 42.4 | 0.47 | 0.63 | - | ||
| 2023/4 | 0.2 | 48.03 | 286.4 | 0.57 | 41.82 | 0.44 | 0.68 | 因新藥/學名藥產品出貨較去年同期多，致本期營收成長 | ||
| 2023/3 | 0.14 | 30.05 | -18.39 | 0.37 | 5.4 | 0.37 | 1.0 | - | ||
| 2023/2 | 0.1 | -18.46 | 37.06 | 0.23 | 27.05 | 0.41 | 0.91 | - | ||
| 2023/1 | 0.13 | -26.58 | 19.92 | 0.13 | 19.92 | 0.59 | 0.62 | - | ||
| 2022/12 | 0.18 | -39.7 | 139.58 | 1.79 | -9.31 | 0.67 | 0.4 | 學名藥產品出貨較去年同期多，故營收增加 | ||
| 2022/11 | 0.29 | 43.04 | 41.79 | 1.61 | -15.04 | 0.67 | 0.4 | - | ||
| 2022/10 | 0.2 | 12.7 | 118.0 | 1.32 | -21.91 | 0.44 | 0.62 | 勞務開發收入本⽉增加，故營收增加 | ||
| 2022/9 | 0.18 | 232.4 | 112.74 | 1.12 | -30.04 | 0.42 | 1.07 | 學名藥產品出貨及勞務開發收入本月增加，故營收增加 | ||
| 2022/8 | 0.05 | -70.9 | -68.39 | 0.94 | -38.01 | 0.44 | 1.01 | 委託開發收入因去年完工比較高，故去年營收較高 | ||
| 2022/7 | 0.19 | -8.52 | 13.58 | 0.89 | -34.14 | 0.48 | 0.93 | - | ||
| 2022/6 | 0.2 | 118.1 | 167.6 | 0.7 | -40.76 | 0.35 | 1.09 | 因新藥/學名藥產品出貨較去年同期多，致本期營收成長 | ||
| 2022/5 | 0.09 | 78.78 | -64.53 | 0.5 | -55.1 | 0.31 | 1.22 | 原料藥產品線因受加徵25%關稅影響，故該產品營收減少 | ||
| 2022/4 | 0.05 | -68.73 | -58.51 | 0.4 | -52.16 | 0.3 | 1.28 | 委託開發收入因去年完工比較高，故去年營收較高 | ||
| 2022/3 | 0.17 | 118.43 | -61.18 | 0.35 | -51.04 | 0.35 | 0.66 | 原料藥產品線因受加徵25%關稅影響，故該產品營收減少 | ||
| 2022/2 | 0.08 | -28.65 | -44.37 | 0.18 | -35.77 | 0.26 | 0.9 | - | ||
| 2022/1 | 0.11 | 46.67 | -27.82 | 0.11 | -27.82 | 0.39 | 0.6 | - | ||
| 2021/12 | 0.07 | -64.31 | -78.84 | 1.97 | -26.29 | 0.37 | 0.57 | 原料藥產品線因受加徵25%關稅影響，故該產品營收減少 | ||
| 2021/11 | 0.2 | 119.92 | -3.94 | 1.9 | -18.5 | 0.38 | 0.55 | - | ||
| 2021/10 | 0.09 | 9.97 | -69.99 | 1.69 | -19.96 | 0.35 | 0.6 | 原料藥產品線因受COVID 19疫情影響及自2019年起需加徵25%關稅,故該產品營收減少 | ||
| 2021/9 | 0.08 | -50.62 | 317.91 | 1.6 | -11.37 | 0.42 | 0.48 | 學名藥產品較去年同期多，故出貨較去年佳 | ||
| 2021/8 | 0.17 | 4.56 | -20.08 | 1.52 | -15.11 | 0.41 | 0.49 | - | ||
| 2021/7 | 0.16 | 115.52 | 40.94 | 1.35 | -14.43 | 0.5 | 0.4 | - | ||
| 2021/6 | 0.08 | -71.09 | 55.63 | 1.18 | -18.85 | 0.47 | 0.52 | 學名藥產品較去年同期多,故出貨較去年佳 | ||
| 2021/5 | 0.26 | 109.11 | -30.19 | 1.11 | -21.44 | 0.82 | 0.29 | - | ||
| 2021/4 | 0.13 | -70.75 | -50.02 | 0.84 | -18.24 | 0.69 | 0.35 | 原料藥產品線因受COVID 19疫情影響及自2019年起需加徵25%關稅,故營收減少 | ||
| 2021/3 | 0.43 | 213.06 | 109.75 | 0.72 | -7.96 | 0.72 | 0.38 | 供應商受疫情影響，原料藥產品遞延至本月到貨故本月營收增加。 | ||
| 2021/2 | 0.14 | -7.43 | -32.35 | 0.29 | -50.1 | 0.63 | 0.43 | 原料藥產品線因受COVID 19疫情影響及自2019年起需加徵25%關稅,故營收減少 | ||
| 2021/1 | 0.15 | -57.01 | -59.84 | 0.15 | -59.84 | 0.71 | 0.38 | 1月份原料藥因供應商受疫情影響，無法如期供貨導致本月營收減少。 | ||
| 2020/12 | 0.35 | 62.06 | -2.43 | 2.68 | -25.64 | 0.87 | 0.36 | - | ||
| 2020/11 | 0.21 | -31.3 | -37.75 | 2.33 | -28.17 | 0.54 | 0.57 | - | ||
| 2020/10 | 0.31 | 1431.78 | 65.47 | 2.12 | -27.04 | 0.55 | 0.57 | 9月份未出貨的貨物已於10月份出貨，故本月營收增加 | ||
| 2020/9 | 0.02 | -90.55 | -93.42 | 1.81 | -33.43 | 0.35 | 0.6 | 9月份原料藥因向供應商進貨之船期延後，貨物無法本月到港，故原料藥營收減少。 | ||
| 2020/8 | 0.21 | 84.43 | -43.54 | 1.79 | -25.75 | 0.38 | 0.55 | - | ||
| 2020/7 | 0.12 | 137.98 | 1.49 | 1.57 | -22.42 | 0.54 | 0.39 | - | ||
| 2020/6 | 0.05 | -87.03 | -91.82 | 1.46 | -23.85 | 0.68 | 0.25 | 受COVID 19疫情影響客戶工廠無法正常運作,故API遞延拉貨.另學名藥因主要原物料藥受國外供應商禁運,導致無法生產,使得營收下滑。 | ||
| 2020/5 | 0.38 | 49.71 | 56.18 | 1.41 | 7.07 | 0.83 | 0.2 | 因貨物提前到港通關運送到客戶處，故本月營收較高。 | ||
| 2020/4 | 0.25 | 22.76 | 6.88 | 1.03 | -3.97 | 0.66 | 0.26 | - | ||
| 2020/3 | 0.21 | 0.95 | -25.06 | 0.78 | -7.03 | 0.78 | 0.31 | - | ||
| 2020/2 | 0.2 | -45.05 | -29.57 | 0.57 | 1.73 | 0.93 | 0.26 | - | ||
| 2020/1 | 0.37 | 4.45 | 34.61 | 0.37 | 34.61 | 1.07 | 0.23 | - | ||
| 2019/12 | 0.35 | 3.39 | -50.7 | 3.6 | -14.12 | 0.0 | N/A | 因107年原物料藥進貨船期集中在12月到貨，故107年12月營收增加 | ||
| 2019/11 | 0.34 | 82.62 | 94.38 | 3.25 | -6.56 | 0.0 | N/A | 因107年原物料藥進貨船期集中在12月到貨，故107年11月營收減少 |
| 加權平均股數 YoY | EPS YoY | 本業EPS YoY | 營收 YoY | 毛利率(%) YoY | 營業利益率 YoY | 稅後淨利率 YoY | 營業利益 YoY | 稅前淨利 YoY | 稅後淨利 YoY | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023 (10) | 114 | 0.0 | -1.27 | 0 | -1.05 | 0 | 2.72 | 51.96 | 62.85 | 47.33 | -59.91 | 0 | -62.65 | 0 | -1.63 | 0 | -1.7 | 0 | -1.45 | 0 |
| 2022 (9) | 114 | -25.0 | -1.41 | 0 | -1.18 | 0 | 1.79 | -9.14 | 42.66 | 66.9 | -90.14 | 0 | -94.13 | 0 | -1.61 | 0 | -1.68 | 0 | -1.61 | 0 |
| 2021 (8) | 152 | 14.29 | -0.99 | 0 | -1.47 | 0 | 1.97 | -26.49 | 25.56 | -18.52 | -107.39 | 0 | -86.43 | 0 | -2.12 | 0 | -1.7 | 0 | -1.5 | 0 |
| 2020 (7) | 133 | 22.02 | -1.30 | 0 | -1.14 | 0 | 2.68 | -25.56 | 31.37 | 218.48 | -59.35 | 0 | -69.06 | 0 | -1.59 | 0 | -1.83 | 0 | -1.73 | 0 |
| 2019 (6) | 109 | 10.1 | -2.48 | 0 | -1.68 | 0 | 3.6 | -14.08 | 9.85 | -18.53 | -60.00 | 0 | -83.05 | 0 | -2.16 | 0 | -2.68 | 0 | -2.72 | 0 |
| 2018 (5) | 99 | 19.28 | -2.45 | 0 | -1.08 | 0 | 4.19 | 12.03 | 12.09 | 24.25 | -56.20 | 0 | -76.10 | 0 | -2.36 | 0 | -3.35 | 0 | -2.42 | 0 |
| 2017 (4) | 83 | 25.76 | -3.50 | 0 | -2.21 | 0 | 3.74 | 14.02 | 9.73 | 91.54 | -87.13 | 0 | -87.46 | 0 | -3.26 | 0 | -3.29 | 0 | -2.92 | 0 |
| 2016 (3) | 66 | 6.45 | -3.84 | 0 | -1.89 | 0 | 3.28 | -29.91 | 5.08 | 18.69 | -82.52 | 0 | -84.98 | 0 | -2.71 | 0 | -2.79 | 0 | -2.55 | 0 |
| 2015 (2) | 62 | 37.78 | -2.34 | 0 | -1.11 | 0 | 4.68 | 106.17 | 4.28 | 21.25 | -32.20 | 0 | -32.32 | 0 | -1.51 | 0 | -1.51 | 0 | -1.45 | 0 |
| 2014 (1) | 45 | 73.08 | -2.23 | 0 | -0.74 | 0 | 2.27 | 127.0 | 3.53 | 0 | -36.28 | 0 | -45.61 | 0 | -0.82 | 0 | -0.87 | 0 | -1.01 | 0 |
